ARTL
HEALTHCAREArtelo Biosciences Inc
$2.78-0.30 (-9.74%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ARTL Today?
No stock-specific AI insight has been generated for ARTL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.64$85.80
$2.78
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-37.56
Dividend Yield—
Dividend / Share—
ROE-16.3%
Profit Margin—
Debt / Equity—
Trading
Volume145K
Avg Volume (10D)—
Shares Outstanding938K
ARTL News
20 articles- Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor DevelopmentYahoo Finance·Apr 28, 2026
- Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class ProfileYahoo Finance·Apr 20, 2026
- Artelo Biosciences Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Apr 7, 2026
- Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswire Inc.·Mar 30, 2026
- Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesYahoo Finance·Mar 27, 2026
- BC-Most Active StocksYahoo Finance·Mar 27, 2026
- Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 TreatmentsYahoo Finance·Mar 25, 2026
- Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma PatientsYahoo Finance·Mar 18, 2026
- Artelo Biosciences announces 3-for-1 reverse stock splitYahoo Finance·Mar 7, 2026
- Artelo Biosciences Announces Reverse Stock SplitYahoo Finance·Mar 6, 2026
- Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial ResultsYahoo Finance·Feb 24, 2026
- Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol CandidateYahoo Finance·Dec 23, 2025
- Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical ModelsYahoo Finance·Dec 3, 2025
- Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in CancerYahoo Finance·Nov 4, 2025
- Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial OfficerYahoo Finance·Oct 27, 2025
- Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development SummitYahoo Finance·Oct 15, 2025
- Artelo Biosciences Announces Closing of $2.0 Million Public OfferingYahoo Finance·Oct 1, 2025
- Artelo Biosciences Announces Pricing of $2.0 Million Public OfferingYahoo Finance·Sep 30, 2025
- Artelo Biosciences Announces Proposed Underwritten Public OfferingYahoo Finance·Sep 29, 2025
All 20 articles loaded
Price Data
Open$3.02
Previous Close$3.08
Day High$3.04
Day Low$2.96
52 Week High$85.80
52 Week Low$2.64
52-Week Range
$2.64$85.80
$2.78
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-37.56
Dividend Yield—
Dividend / Share—
ROE-16.3%
Profit Margin—
Debt / Equity—
Trading
Volume145K
Avg Volume (10D)—
Shares Outstanding938K
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—